ClinicalTrials.gg
CompletedNCT06877702Updated Jan 20, 2026

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

A Phase 1 interventional study of BMS-986460 in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BMS-986460, bioavailability, healthy adult male, crossover, SAD
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy as determined by no deviation from normal in medical history, physical examination, vital signs, 12-lead ECGs, echocardiogram or clinical laboratory assessments, as determined by the investigator.
  • Participants must have a (BMI) between 18.0 and 35.0 kilograms/meter square (kg/m2), inclusive.
  • Male participants who are sexually active with individuals of (IOCBP) must agree to follow instructions for methods of .

Exclusion criteria

Exclusion Criteria:

  • Participants with prior exposure to BMS-986460 or with a prior history of heart failure, ischemic heart diseases, cardiac arrythmias, or long syndrome are excluded.
  • Participants with (≤ 50%) at screening are excluded.
  • Participants with history of anaphylactic reactions are excluded.
  • Participants with current or recent (within 3 months of intervention administration) gastrointestinal disease that, in the opinion of the investigator, could affect the absorption of study intervention are excluded.
  • Participants with history of Gilbert's syndrome are excluded.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Part 1: Sequence 1

    Drug: BMS-986460

  • Experimental
    Part 1: Sequence 2

    Drug: BMS-986460

  • Experimental
    Part 1: Sequence 3

    Drug: BMS-986460

  • Experimental
    Part 2: Treatment A

    Drug: BMS-986460

  • Experimental
    Part 2: Treatment B

    Drug: BMS-986460

  • Experimental
    Part 2: Optional Treatment C

    Drug: BMS-986460

  • Experimental
    Part 2: Optional Treatment D

    Drug: BMS-986460

  • Experimental
    Part 2: Optional Treatment E

    Drug: BMS-986460

Interventions

  • DrugBMS-986460

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately Day 43

  2. Part 1: Number of Participants With Serious AEs (SAEs)

    Time frame: Up to approximately Day 43

  3. Part 1: Number of Participants With Clinically Significant Physical Evaluation (PE) Findings

    Time frame: Up to approximately Day 21

  4. Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities

    Time frame: Up to approximately Day 21

  5. Part 1: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities

    Time frame: Up to approximately Day 21

  6. Part 1: Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings

    Time frame: Up to approximately Day 21

  7. Part 1: Maximum Observed Plasma Concentration (Cmax) of BMS-986460

    Time frame: Up to approximately Day 21

  8. Part 1: Time of Maximum Plasma Observed Concentration (Tmax) of BMS-986460

    Time frame: Up to approximately Day 21

  9. Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-T]) of BMS-986460

    Time frame: Up to approximately Day 21

  10. Part 1: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986460

    Time frame: Up to approximately Day 21

  11. Part 1: Relative Bioavailability (rBA) of Alternate Formulations of BMS-986460 as Compared to Reference Formulation Based on Geometric Mean Ratio (GMR) of Cmax

    Time frame: Up to approximately Day 21

  12. Part 1: rBA of Alternate Formulations of BMS-986460 as Compared to Reference Formulation Based on GMR of AUC(0-T)

    Time frame: Up to approximately Day 21

  13. Part 1: rBA of Alternate Formulations of BMS-986460 as Compared to Reference Formulation Based on GMR of AUC(INF)

    Time frame: Up to approximately Day 21

  14. Part 2: Number of Participants With AEs

    Time frame: Up to approximately Day 29

  15. Part 2: Number of Participants With SAEs

    Time frame: Up to approximately Day 29

  16. Part 2: Number of Participants With Clinically Significant PE Findings

    Time frame: Up to approximately Day 7

  17. Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities

    Time frame: Up to approximately Day 7

  18. Part 2: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities

    Time frame: Up to approximately Day 7

  19. Part 2: Number of Participants With Clinically Significant 12-lead ECG Findings

    Time frame: Up to approximately Day 7

  20. Part 2: Cmax of BMS-986460

    Time frame: Up to approximately Day 7

  21. Part 2: Tmax of BMS-986460

    Time frame: Up to approximately Day 7

  22. Part 2: AUC [0-T] of BMS-986460

    Time frame: Up to approximately Day 7

  23. Part 2: AUC(INF) of BMS-986460

    Time frame: Up to approximately Day 7

Secondary outcomes

  1. Part 2: Pharmacokinetic (PK) Linearity of BMS-986460 Based on Cmax

    Time frame: Up to approximately Day 7

  2. Part 2: PK Linearity of BMS-986460 Based on AUC(0-T)

    Time frame: Up to approximately Day 7

  3. Part 2: PK Linearity of BMS-986460 Based on AUC(INF)

    Time frame: Up to approximately Day 7

07

Study locations

1 site
  • Local Institution - 0001
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Dec 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Mar 19, 2025
Primary completionActual
Dec 17, 2025
CompletionActual
Dec 17, 2025
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06877702
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Mar 19, 2025
Primary completion
Dec 17, 2025
Completion
Dec 17, 2025
Last update
Jan 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion